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Abstract
The levels of methyl-CpG–binding protein 2 (MeCP2) are critical for normal post-natal development and function of the
nervous system. Loss of function of MeCP2, a transcriptional regulator involved in chromatin remodeling, causes classic Rett
syndrome (RTT) as well as other related conditions characterized by autism, learning disabilities, or mental retardation.
Increased dosage of MeCP2 also leads to clinically similar neurological disorders and mental retardation. To identify
molecular mechanisms capable of compensating for altered MeCP2 levels, we generated transgenic Drosophila
overexpressing human MeCP2. We find that MeCP2 associates with chromatin and is phosphorylated at serine 423 in
Drosophila, as is found in mammals. MeCP2 overexpression leads to anatomical (i.e., disorganized eyes, ectopic wing veins)
and behavioral (i.e., motor dysfunction) abnormalities. We used a candidate gene approach to identify genes that are able
to compensate for abnormal phenotypes caused by MeCP2 increased activity. These genetic modifiers include other
chromatin remodeling genes (Additional sex combs, corto, osa, Sex combs on midleg, and trithorax), the kinase tricornered, the
UBE3A target pebble, and Drosophila homologues of the MeCP2 physical interactors Sin3a, REST, and N-CoR. These findings
demonstrate that anatomical and behavioral phenotypes caused by MeCP2 activity can be ameliorated by altering other
factors that might be more amenable to manipulation than MeCP2 itself.
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Introduction
Research in the last decade has linked the methyl-CpG-binding
protein 2 (MeCP2) with a variety of related neurological disorders
[1]. Loss of MeCP2 function causes classic Rett syndrome (RTT),
but can also lead to related neurological conditions with symptoms
that include autism, mild or severe mental retardation with
seizures, or learning disabilities [2,3]. Increased dosage of the
MECP2 locus also leads to RTT-like features and severe mental
retardation [4–6]. Similar phenotypes are recapitulated in mice
that either lack or overexpress MECP2, thus underscoring the
importance of properly regulating MeCP2 levels [7–10]. The
MeCP2 protein contains a methyl-CpG-binding domain (MBD)
and localizes to the heterochromatin where it is believed to
regulate gene expression by recruiting histone deacetylases to alter
chromatin structure [11,12]. While an ortholog for the complete
MeCP2 protein does not exist in Drosophila, methyl-CpG-binding
domains are conserved from flies to humans [13]. MeCP2 also
interacts with other proteins involved in transcriptional repression
and chromatin remodeling including Sin3a, REST and Brahma, a
core component of the SWI/SNF complex [14–16]. These and
other previously identified MeCP2 interactors have well conserved
orthologs in Drosophila (Table S1), as do most components of the
chromatin remodeling machinery. Examples of evolutionarily
conserved chromatin remodeling proteins include members of the
Polycomb and trithorax groups (Pc-G and trx-G, respectively), as
well as proteins involved in histone tail modification [17,18]. Many
of these proteins act in protein complexes that function
antagonistically to promote either activation or repression of
target genes [17,19–21]. Therefore, we hypothesized that genetic
screening in transgenic flies expressing human MeCP2 may permit
the identification of genes capable of compensating the phenotypes
caused by altered MeCP2 levels. These genetic modifiers may
include genes that function antagonistically to MeCP2 in
chromatin remodeling, and perhaps other genes modulating
MeCP2 functions or interactions. Here we report the identification
of such genes.
Results
Expression of Human MeCP2 in Drosophila
We generated transgenic flies overexpressing wild-type MeCP2
as well as three mutant alleles using the human MECP2_e2 cDNA
(Figure 1A). The RTT R106W allele produces a missense
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bind DNA [22]. The RTT R294X mutation truncates the protein
within the transcriptional repression domain (TRD), but maintains
the nuclear localization signal. The D166 allele completely
removes the MBD and N-terminal portion of the protein.
Constructs were created inserting each allele into the pUAST
vector to utilize the GAL4-UAS system [23]. This system
controls expression in specific cell types depending on the Gal4
driver line used, and can be modified by varying the
temperature of the fly cultures – increased temperature leads
to increased expression.
Independent MeCP2 transgenic lines of each allele were
generated and tested to ensure that any resulting phenotypes
were not caused by the insertion site. Using GMR-Gal4 to drive
transgene expression in the eye [24], we confirmed protein
expression by western blot analysis using extracts from whole fly
heads (Figure 1B). Furthermore, we found that all three MeCP2
alleles that retain amino acid S423, which corresponds to murine
S421, produce protein that is specifically phosphorylated at this
site (Figure 1C). This specific signal was abolished when the
protein extract was treated with alkaline phosphatase (Figure 1D).
Phosphorylation at this serine in mammals is brain specific, and it
is required by MeCP2 to control dendritic patterning, spine
morphogenesis and to regulate the BDNF target gene [25].
Therefore, this key posttranslational modification is conserved
when MeCP2 is expressed in Drosophila.
Association of MeCP2 with chromatin is a functional property
of the mammalian protein [12], and was evaluated by
promoting MeCP2 expression with the ubiquitous Actin5c-Gal4
driver. Immunofluorescent staining of squashed salivary glands
demonstrated that MeCP2 localizes to the nucleus and associates
with polytene chromosomes along many bands in all four alleles
(Figure 1E-I’’). While there is widespread association, MeCP2
does not localize to all polytene bands, suggesting target
specificity. Association with the polytene chromosomes does
not solely depend upon the MBD or C-terminal regions since all
four proteins behave similarly. The ability of the R106W and
D166 mutants to associate with chromosomes implies that the
methyl-CpG-binding domain is not required for this activity.
Additional factors, possibly functioning in various protein
complexes with MeCP2, may act to recruit MeCP2 to the
chromatin.
Phenotypes Caused by MeCP2 Overexpression in
Drosophila
MeCP2 overexpression in the fly eye by GMR-Gal4 was utilized
as an assay for rapid genetic screening of modifiers. Overexpres-
sion of multiple independent lines of all four alleles resulted in
external eye phenotypes of varying degrees (Figure 2A–E). Lines
expressing comparable protein levels were selected for each allele
(Figure 1B). The full-length wild-type, R106W and D166 lines
cause a disruption of the external structure of the eye that is
recognized as a ‘‘glassy’’ effect on the surface when observed by
light microscopy (Figure 2A–D). When evaluated by scanning
electron microscopy, these same animals show disorganized
ommatidia and partial loss of interommatidial bristles
(Figure 2A’–D’). These features were enhanced in flies cultured
at a higher temperature (Figure 2A’’–D’’) as a result of elevated
expression levels. Of all four alleles, the full-length protein causes
the strongest disruption to the external eye. While the R294X
allele does not cause an obvious disruption of the external eye
structure, it shows a loss of pigmentation phenotype (Figure 2E,
2E’, and data not shown), which had only been seen in one of the
most strongly expressing full-length lines. Moreover, expression of
the R294X allele at a higher temperature is lethal, possibly a
consequence of the leaky expression of the GMR-Gal4 driver into
other tissues.
We also overexpressed MeCP2 in other fly tissues. Expression of
the full-length protein in the wing pouch by C5-Gal4 produces
extra vein tissue around the L3 and L5 wing veins (Figure 2F, G).
Furthermore, neuronal expression of full-length MeCP2 by the
CHA-Gal4 driver [26] leads to impaired motor function in adult
flies as measured in a climbing assay (Figure 2H, Video S1). While
external eye phenotypes are most practical for primary screening
to identify novel genetic modifiers of MeCP2, both the wing vein
and climbing phenotypes are valuable as secondary screening
assays to validate genetic interactions.
Genetic Modifiers of MeCP2
We rationalized that in vivo genetic modifiers of MeCP2 function
might be enriched among known MeCP2 physical interactors. In
support of this hypothesis we previously showed that a large
proportion of the physical interactors of huntingtin (the protein
that when mutant causes Huntington’s disease) are also genetic
modifiers of huntingtin-induced neurodegeneration [27]. To test
this hypothesis in the case of MeCP2, we evaluated Sin3A, Smrter,
and crooked legs, the Drosophila homologs of Sin3a, N-CoR, and REST
(Table S1) [28,29]. We found that heterozygous loss-of-function
mutations in each of these three direct interacting partners alter
the MeCP2 eye phenotype (Table 1, Figure 3).
We then tested other candidate modifier genes that were chosen
based on their functions. In addition to chromatin remodeling
genes, these included a collection of kinases because MeCP2 is
phosphorylated [25], and two genes implicated in Angelman
syndrome, a disorder that shares clinical features with Rett
syndrome. These last two candidates are the Drosophila homolog of
UBE3A, the gene encoding a ubiquitin ligase misregulated in
Angelman syndrome, and its target pebble [30,31]. When available,
both loss-of-function and overexpression mutant Drosophila lines of
each candidate were collected. A total of 584 mutant Drosophila
lines were obtained and screened against the full-length MeCP2
allele; 392 lines representing 158 individual kinases, 174 lines
representing 54 unique chromatin remodeling genes, and 18 lines
encompassing UBE3A and pebble mutants.
Author Summary
Rett syndrome (RTT) is a progressive neurodevelopmental
disorder that affects girls early in childhood and is caused
by mutations in the MECP2 gene. Loss of MeCP2 function
can also lead to clinically distinct conditions characterized
by autism, learning disability, and mental retardation.
Remarkably, increased levels of MeCP2 leads to related
neurological disorders and mental retardation as well.
These data emphasize the critical importance of regulating
MeCP2 protein levels for normal post-natal development
and function of the nervous system. MeCP2 is a protein
that associates with chromatin and is thought to modulate
gene expression. We have generated Drosophila that
overexpress human MeCP2 to investigate the possibility
that adjusting the activity of other genes may compensate
for altered levels of MeCP2. In support of this hypothesis,
we found a variety of modifier genes, including chromatin
remodeling genes, that are able to ameliorate and/or
aggravate the consequences of MeCP2 overexpression.
These findings open the possibility of therapeutic avenues
for RTT and related neuropsychiatric disorders by targeting
proteins that are possibly easier to manipulate than MeCP2
itself.
Genetic Modifiers of MeCP2
PLoS Genetics | www.plosgenetics.org 2 September 2008 | Volume 4 | Issue 9 | e1000179Figure 1. MeCP2 alleles used to generate transgenic Drosophila: protein expression, phosphorylation at serine 423, and association
with polytene chromosomes. A. Four MECP2 alleles were cloned into pUAST to generate transgenic flies. The methyl-CpG-binding domain (MBD)
is represented by blue boxes and the transcription repression domain (TRD) is represented by green boxes. The nuclear localization signal (NLS) falls
within the TRD. B. Western blot analysis demonstrates expression of each of the alleles when driven by GMR-Gal4. Two distinct MeCP2 antibodies
were utilized in order to recognize each allele to confirm that a deletion removed an epitope region. C. Immunoblot with a phospho-specific
antibody shows phosphorylation in the three alleles retaining amino acid S423. D. Immunoblot with the phospho-specific MeCP2 S423 antibody in
negative control, extracts from MeCP2 expressing flies when treated with calf intestinal phosphatase and untreated MeCP2 extracts. The treated
samples fail to produce a band with the phospho-specific antibody, but demonstrate MeCP2 expression with the whole MeCP2 antibody (E-I’’).
Immunoflourescence of squashed polytene chromosomes dissected from 3rd instar larvae raised at 25uC. Control larvae do not have MeCP2
immunoreactivity (E-E’’). All MeCP2 alleles demonstrate accumulation of the MeCP2 protein in banded pattern along the polytene chromosomes
(F-I’’).
doi:10.1371/journal.pgen.1000179.g001
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flies expressing the full-length MeCP2 allele from the GMR-Gal4
driver and screened for both enhancers and suppressors. The
initial hits in this screen were then re-evaluated with an
independent full-length MeCP2 transgenic line. Genes that modify
the MeCP2 phenotypes across multiple strains and MeCP2 lines
are the chromatin remodeling genes Additional sex combs (Asx), corto,
osa, Sex combs on midleg (Scm), and trithorax (trx), the kinase tricornered
(trc) and the UBE3A target pebble (pbl) (Table 1). Partial loss of
function of Asx, corto, osa, pebble,o rScm suppress the eye phenotype
induced by full-length MeCP2, while trc has a similar effect when it
is overexpressed (Figure 4A–H, note improved ommatidial
organization relative to MeCP2 control). In contrast, enhance-
ment of the eye phenotype was observed in MeCP2 animals with
either loss-of-function mutations in trx or overexpression alleles of
Scm, osa, and pbl (Figure 4I-4R, Figure S1, note greater ommatidial
disruption, loss of interommatidial bristles and, in some cases,
reduction in eye size and eye depigmentation). To exclude the
possibility that modifiers of the Gal4-UAS system may simply
cause changes in expression of MeCP2, western blot analysis was
Figure 2. MeCP2 overexpression leads to eye, wing and motor performance phenotypes. Light microscope images (A–E), and scanning
electron microscope images (A’–D’’) of fly eyes from controls or animals expressing MeCP2 driven by GMR-Gal4 driver at either 27.5uCo r3 0 uC.
External eyes of control flies show normal ommatidial organization, while eyes from animals expressing any of four distinct MeCP2 alleles show
disruption in the structured pattern of the eye the surface. Note increased severity of the phenotypes at the higher temperature. F–G. The C5-Gal4
driver was used to drive either UAS-lacZ or full-length MeCP2 throughout the wing pouch at 25uC. Compared to controls, MeCP2 expressing flies
have extra vein tissue (arrowheads) near L3 and L5. H. The neuronal driver CHA-Gal4 was used to drive expression of either UAS-eGFP or full-length
MeCP2 at 25uC. Each sample represents a group of 20 virgin females. Beginning at 3 days of age, a lower percent of MeCP2 expressing flies are able
to climb to 7 cm in 18 seconds as compared to control flies (Repeated measures ANOVA p,0.001). Over time, both groups decrease in their ability to
climb. Error bars represent the standard error. Genotypes: A-A’’, GMR-Gal4/+. B-B’’, GMR-Gal4:UAS-MeCP2
FLM119-2M/+. C-C’’, GMR-Gal4:UAS-MeCP2
R106W/+. D-D’’, GMR-Gal4:UAS-MeCP2 D166/+. E-E’, GMR-Gal4:UAS-MeCP2 R294X/+. F, C5-Gal4/+.G ,C5-Gal4:UAS-MeCP2
FLM119-1M/+.H ,CHA-Gal4/UAS-
eGFP and CHA-Gal4/UAS-MeCP2
FLM119-2M.
doi:10.1371/journal.pgen.1000179.g002
Genetic Modifiers of MeCP2
PLoS Genetics | www.plosgenetics.org 4 September 2008 | Volume 4 | Issue 9 | e1000179performed and demonstrated that the modifiers did not alter the
level of MeCP2 protein (Figure S2).
Each modifier line found to alter the full-length MeCP2
phenotype was also investigated in the context of the D166 and
R294X MeCP2 alleles to determine if the modification was
dependent upon a specific MeCP2 domain. For the MeCP2 D166
allele, all genetic modifiers behaved similarly to the full-length
MeCP2 allele (Table 1, Figure S3).
Since the MeCP2 R294X allele does not dramatically alter the
structure of the eye, suppression was assessed primarily by gain in
the amount of eye pigmentation. Enhancement was assessed by
increased loss of pigmentation and/or disruption in the external
structure of the eye. We found similar phenotype modifications as
with full-length MeCP2 with two interesting exceptions (Table 1
and Figure S4). Partial loss of Sin3A function, which enhances
full-length MeCP2 (compare Figures 3B and 3C), suppresses
MeCP2 R294X phenotypes (compare Figures S4D and S4A).
Partial loss of trx function, which enhances the full-length MeCP2
phenotype (compare Figures 4B and 4I), but, in the case of the
trx
E2 allele suppresses the R294X phenotype (compare Figures
S4A and S4P).
The candidate suppressor genes were then further tested against
the full-length MeCP2 allele in a second independent assay using
the L3 wing vein phenotype (Figure 5A–E). Indeed, alleles of Asx,
osa, Scm and trc are able to decrease the penetrance of the L3 wing
vein phenotype. Furthermore, loss of function of osa and
Table 1. Genetic Modifiers of MeCP2.
MeCP2 alleles
Drosophila Gene, Flybase ID
Mammalian Homolog(s) Modifier Allele Full length D166 R294X
crooked legs (crol), FBgn0020309 c04670 (LOF) sup sup sup
RE1 silencing transcription factor (REST) e0407 (LOF) sup sup sup
Sin3a, FBgn0022764 dQ4 (LOF) enh enh sup
Sin3a
Smrter (Smr), FBgn0024308 e04377 (LOF) sup sup sup
nuclear receptor co-repressor (N-CoR) e04389 (LOF) sup sup no mod
Additional sex combs (Asx) 1 (GOF) enh enh enh
FBgn0000141 EY07384 (LOF) sup sup sup
Additional Sex Combs like 1(Asxl1) XF23(LOF) sup sup sup
corto, FBgn0010313 07128b (LOF) sup sup sup
Mastermind like 2 (Maml2) c03244 (LOF) sup sup sup
e02822 (LOF) sup sup sup
osa, FBgn0003013 00090 (LOF) sup sup sup
AT-rich interaction domain 1a & 1b 308 (LOF) sup sup sup
(Arid1a, Arid1b) EY09619 (LOF) sup no mod sup
UAS-osa (OE) enh enh enh
pebble (pbl), FBgn0003041 2 (LOF) sup no mod sup
Epithelial cell transforming 3 (LOF) sup no mod sup
sequence 2(Ect2) 5 (LOF) sup no mod sup
09645 (LOF) sup no mod no mod
UAS-pebble (OE) enh enh enh
Sex combs on midleg (Scm) e01989 (LOF) sup sup no mod
FBgn0003334 D1 (LOF) sup no mod sup
Sex combs on midleg homolog 1(Scmh1) ET50e (LOF) sup sup no mod
M36 (LOF) sup sup sup
M56 (LOF) sup sup sup
UAS-scm (OE) enh enh no mod
XF24 (LOF) sup sup sup
tricornered (trc), FBgn0003744 UAS-trc LD (OE) sup sup sup
Nuclear Dbf-related 1 & 2 (Ndr1, Ndr2) UAS-trc wtn (OE) sup sup sup
trithorax (trx), FBgn0003862 1 (hypomorph) enh enh no mod
Mixed lineage leukemia (Mll) E2 (amorph) enh enh sup
KG04195 (LOF) enh enh no mod
LOF: loss of function, GOF: gain of function, OE: overexpression.
no mod: no clear modification with this particular allele.
doi:10.1371/journal.pgen.1000179.t001
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neuronal-specific expression of MeCP2 (Figure 5F). Consistent
modification of MeCP2 phenotypes in different tissues, including a
behavioral phenotype caused by neural-specific expression,
provides additional evidence for the capacity of theses genes to
modulate MeCP2 function.
Discussion
We have used the Drosophila model system to facilitate the
identification of genes capable of counterbalancing the conse-
quences of altered levels of the human MeCP2 protein. First, we
established anatomical and behavioral assays to assess the effects of
expressing human MeCP2 in flies. We used an eye phenotype as a
primary assay for the genetic screen, and impaired motor
performance and other phenotypes as secondary assays for
validating purposes. The eye phenotype has been used successfully
in a variety of genetic screens including screens for enhancer/
suppressors of other neurological disease models. Although
expression of a variety of ‘‘toxic’’ human proteins leads to
apparently similar ‘‘rough’’ eye phenotypes, their specificity is
demonstrated when comparing the genetic modifiers uncovered in
the screens. For example, there is little or no overlap between the
MeCP2 modifiers reported here and modifiers of the eye
phenotype produced by expression of ataxin-1 [32,33] or
huntingtin [27]. In contrast, we found that the majority of the
modifier genes modulating the eye phenotype caused by wild-type
MeCP2 similarly modulate the phenotypes caused by the R294X
and D166 MeCP2 mutations. Two exceptions are Sin3A and trx,
which have opposite effects on wild-type and R294X MeCP2
(Table 1, Figures 3B, C versus Figures S4A, D, and Figures 4B, I
versus Figures S4A, P). MeCP2 associates with a co-repressor
complex containing Sin3A through the TRD domain [14], which
is partially deleted in the truncated R294X protein. This mutant
also lacks the MeCP2 C-terminal region that is important for
interactions with chromatin in vitro [34]. The TRD domain and/
or C-terminal region may thus be involved in the observed genetic
interaction between MeCP2 and trx. It is important to note that
both Sin3A and trx do modify the eye phenotype of R294X MeCP2
animals, albeit in the opposite way from the wild-type MeCP2.
Thus, the TRD/C-terminal domains may play a modulating role
rather than being required for the interaction.
A commonly accepted model of MeCP2 function postulates that
MeCP2 binds to methylated CpG islands in promoters where it
recruits histone deacetylases and other co-repressors to silence
gene transcription [14,35]. However, accumulating evidence
Figure 3. Known MeCP2 physical interactors are also genetic modifiers of the MeCP2 eye phenotype. A–C. SEM images of the external
eye of a control, a fly expressing full-length MeCP2, and full-length MeCP2 in the presence of a heterozygous loss-of-function allele of Sin3A cultured
at 27.5uC. Reduced Sin3A activity enhances the disorganization of the ommatidia in the eye. D–G. SEM images of the external eye of a control, a fly
expressing full-length MeCP2, and full-length MeCP2 in the presence of either loss-of-function of crooked legs or Smrter cultured at 30uC. Both alleles
suppress the ommatidial disorganization caused by MeCP2 expression in the eye. Genotypes: A. GMR-Gal4/+. B, GMR-Gal4:UAS-MeCP2
FLM119-1M/+. C,
GMR-Gal4:UAS-MeCP2
FLM119-1M/Sin3A
dQ4. D, GMR-Gal4/+. E, GMR-Gal4:UAS-MeCP2
FLM119-2M/+. F, GMR-Gal4:UAS-MeCP2
FLM119-2M/crol
d03416. G, Smr
e04389/
+; GMR-Gal4:UAS-MeCP2
FLM119-2M/+.
doi:10.1371/journal.pgen.1000179.g003
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PLoS Genetics | www.plosgenetics.org 6 September 2008 | Volume 4 | Issue 9 | e1000179Figure 4. Novel genetic modifiers of the MeCP2 eye phenotype. A–B. MeCP2 expression by GMR-Gal4 at 30uC causes severe disorganization
of the ommatidia and interommatidial bristles compared to controls. C–H. This phenotype is alleviated when combined with loss-of-function mutants
in Asx, corto, osa, pbl, Scm, or overexpression of trc. I. In contrast, the loss-of-function trx allele enhances the external eye phenotype. J–L. When
MeCP2 is driven by GMR-Gal4 at 27.5uC, the mild eye phenotype of MeCP2 is enhanced when combined with overexpression of Scm. M–R. Even
though the MeCP2 flies do not show an eye phenotype at 25uC (N), when combined with either overexpression of osa (O) or pbl (Q), a strongly
disrupted phenotype results that causes a loss of interommatidial bristles and, in the case of pbl, a reduction in the number of ommatidia. When osa
and pbl are overexpressed alone, they have very mild phenotypes (P, R). Genotypes: A, GMR-Gal4/+. B, GMR-Gal4:UAS-MeCP2
FLM119-2M/+. C, GMR-
Gal4:UAS-MeCP2
FLM119-2M/Asx
XF23. D, GMR-Gal4:UAS-MeCP2
FLM119-2M/+; corto
c03244/+. E, GMR-Gal4:UAS-MeCP2
FLM119-2M/+; osa
00090/+. F, GMR-Gal4:
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For example, MeCP2 binds to unmethylated DNA with affinity
only 3 times weaker than to methylated DNA [36], and MeCP2
also binds [37] or requires AT sequences for binding [38].
Moreover, MeCP2 interacts with both methylated and unmethy-
lated chromatin and leads to alterations in the secondary structure
of both types of chromatin [34,39]. In addition, large-scale
mapping of MeCP2 binding sites in chromosomal regions
containing candidate MeCP2 target genes revealed that: 1)
MeCP2 is absent from highly methylated promoters, 2) only
,6% of MeCP2 binding sites are in CpG islands, and 3) many
MeCP2-bound promoters are actively expressed [40]. Further-
more, a recent study of gene expression patterns in mice that either
lack or overexpress MeCP2 suggests that many genes are activated
by MeCP2 [41]. Here we show that the methyl-CpG-binding
domain is not necessary for association of the MeCP2 protein with
chromatin in polytene chromosomes (Figures 1H-H’’), nor is it
required to produce an eye phenotype in Drosophila (Figures 2D-
D’’). In this context it is interesting to note that unlike mammals,
bacteria, plants, and other insects, the levels of DNA methylation
are very low in Drosophila [42]. Together these data suggest that
MeCP2 function may be more complex than previously thought.
MeCP2 may regulate both methylated and unmethylated target
genes in vivo, possibly as part of large protein complex(es) of
chromatin remodelling proteins regulating gene expression both
positively and negatively.
Using a candidate gene approach, we provide proof of principle
that modulating the activity of modifier genes can amend MeCP2
function in vivo. Among this group of genes is the kinase trc,a
member of the NDR (nuclear Dbf-related) family. We could not
detect alterations in the phosphorylation of MeCP2 in trc mutants
(data not shown). However, there is evidence that both trc and one
Figure 5. Genetic modifiers of the MeCP2 eye phenotype also suppress the L3 wing vein phenotype, and the motor impairment
caused by neuronal overexpression of MeCP2. A–B. Expression of MeCP2 in the wing pouch by the C5-Gal4 driver causes extra wing vein tissue
(arrowheads near L3 and L5 veins) as compared to control flies. C–D. This phenotype is suppressed by genetic modifiers of the external eye
phenotype including osa and Scm. E. Quantification of the L3 wing vein phenotype demonstrates that alleles of Asx, osa, Scm, and trc are all able to
significantly suppress the wing vein phenotype (p,0.05 in all cases). F. Overexpression of full-length MeCP2 by the neuronal driver CHA-Gal4 leads to
a motor function impairment as measured in a climbing assay that becomes more severe over time. When MeCP2 is expressed in the presence of
either a loss-of-function osa
00090 allele or the gain of function UAS-trc
LD allele, the severity of the climbing phenotype is reduced (Repeated measures
ANOVA p,0.001 at day 13 for osa
00090, and for UAS-trc
LD at day 10). Each sample represents an initial group of 20 virgin female flies except one
control group which had 15 virgin flies. Error bars represent the standard error. Experiment was performed in duplicate yielding similar results, but
only one data set is shown.
doi:10.1371/journal.pgen.1000179.g005
UAS-MeCP2
FLM119-2M/+; pbl
09645/+. G, GMR-Gal4:UAS-MeCP2
FLM119-2M/+; Scm
e01989/+. H, GMR-Gal4:UAS-MeCP2
FLM119-2M/+; UAS-trc
LD/+. I, GMR-Gal4:UAS-
MeCP2
FLM119-2M/+; trx
KG04195/+. J, GMR-Gal4/+. K, GMR-Gal4:UAS-MeCP2
FLM119-2M/+. L, GMR-Gal4:UAS-MeCP2
FLM119-2M/+; UAS-Scm/+. M, GMR-Gal4/+. N,
GMR-Gal4:UAS-MeCP2
FLM119-2M/+. O, GMR-Gal4:UAS-MeCP2
FLM119-2M/UAS-osa. P, GMR-Gal4/UAS-osa. Q, GMR-Gal4:UAS-MeCP2
FLM119-2M/UAS-pbl. R,
GMR-Gal4/UAS-pbl.
doi:10.1371/journal.pgen.1000179.g004
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formation [43,44], a feature also found to be affected by mutations
in MeCP2. Also, modification of the MeCP2 phenotype by the E3
ligase UBE3A target pbl [31] is noteworthy due to the similarities
between Rett and Angelman syndromes. Patients with Angelman-
like features have been identified with MeCP2 mutations [45,46]
and, while still controversial, some studies have demonstrated a
decrease of UBE3A in Rett patients and Mecp2 null mice [47–49].
The data presented here suggest that shared pathways may be
involved in Rett and Angelman syndromes.
Misregulation of neuronal genes caused by alterations in
MeCP2 activity is thought to cause Rett and Rett-like syndromes
[50,51]. One possible avenue for therapy is to identify the MeCP2
target genes misregulated during disease and to restore their
normal regulation. This approach may prove impractical if the
targets are numerous or difficult to identify due to subtle variations
in expression levels in response to MeCP2 activity [52–57]. A
possible future treatment based on gene therapy to restore normal
levels of MeCP2 also seems improbable. The nervous systems of
Rett patients are mosaic due to random X-chromosome
inactivation causing some neurons expressing the normal while
others expressing the mutant allele. Therefore, in the context of
neurons expressing the wild-type allele, gene therapy is not
possible because doubling of MeCP2 also leads to disease [5,6,58].
An alternative approach is to identify molecular mechanisms
capable of compensating for the misregulation of target genes
caused by MeCP2 altered levels. This study provides support for
the validity of this approach. We identified specific chromatin
remodeling genes of the Pc-G and Trx-G (i.e., Asx, corto, osa, and
Scm) that suppress the phenotypes caused by MeCP2 overexpres-
sion in Drosophila. Interestingly, both in Drosophila and mammals,
mutations in genes of either Pc-G or Trx-G also suppress the body
patterning abnormalities caused by mutations in members of the
other group [17,19].
In conclusion, human MeCP2 protein expressed in Drosophila
maintains important features observed in mammals such as
phosphorylation and association with the chromatin. The novel
modifiers identified in this model system point to potential
therapeutic targets that might be more amenable to manipula-
tion than MeCP2, and thus they provide new opportunities to
develop therapies for Rett syndrome and related neurological
disorders.
Methods
Generation of MeCP2 Constructs and Drosophila Lines
Each of the MeCP2 alleles described was cloned into the
pUAST vector in order to utilizing the GAL4-UAS system
(Figure 1A). The full-length human cDNA of the MECP2_e2
isoform (1461 nucleotides, 486 amino acids) was subcloned into
the EcoRI site of the pUAST vector. The remaining three alleles
were generated by PCR mutagenesis of this initial construct.
MeCP2 R294X was amplified with primers that attached a stop
codon and Kpn I site to the C-terminal end. This PCR fragment
was digested with EcoRI and Kpn I and then ligated between
these restriction sites in pUAST. Primers amplifying the MeCP2
D166 fragment added an EcoRI site, a conserved Drosophila
consensus sequence (TCGAC), and an ATG start site to the N-
terminal side of the protein. Transgenic Drosophila lines were
generated by injection of these constructs in embryos following
standard methods. We generated eleven MeCP2 full-length lines,
ten MeCP2 R106W lines, three MeCP2 R294X lines and ten
MeCP2 D166 lines. Additional Drosophila lines were obtained from
the Bloomington Drosophila Stock Center, the Harvard Medical
School Exelixis Drosophila Stock Collection, and private investiga-
tors (see acknowledgements).
Western Blot Analysis and Alkaline Phosphatase
Treatment
Protein was collected from Drosophila heads in a solution of 5%
b-mercaptoethanol in Laemmli Sample Buffer (Bio-Rad). For the
alkaline phosphatase treatment, Drosophila heads were collected in
protein extraction buffer (PBS with 0.1% Nonident P40 and
protease inhibitors), samples were smashed and kept on ice for
1 hour, vortexing each 10 minutes in order to facilitate protein
extraction. Samples were then mixed 1:1 with the calf intestinal
alkaline phosphatase (CIP) treatment, 10% CIP enzyme (New
England Biolabs), 30% CIP buffer in water, and incubated for
50 minutes at 37uC. Laemmli Sample Buffer was then added to
these reactions. Proteins were run on SDS-PAGE gels with eight
Drosophila heads per lane (except for the alkaline phosphatase
experiment which had ten heads per lane). Proteins were then
transferred to nitrocellulose membrane (Optitran) using 10mM
CAPS with 10% methanol. Membranes were blocked in
BLOTTO 5% Non-Fat Dry Milk (Bio-Rad) in TBS-T (100mM
Tris-Cl pH 7.5, 150mM NaCl, 0.1% Tween 20). The following
antibodies were used diluted in BLOTTO: anti-MeCP2 antibodies
(1:1000, Upstate, #07-013, and Affinity, #PA1-887), anti-lamin C
(1:1000, Developmental Studies Hybridoma Bank, #LC28.26),
and anti-tubulin (1:5000, Developmental Studies Hybridoma
Bank, #E7). Anti-phosphorylated MeCP2 S423 was diluted in
5% BSA (1:1000) [25]. Anti-rabbit and anti-mouse horseradish
peroxidase-conjugated secondary antibodies (Bio-Rad) were dilut-
ed 1:5000 in BLOTTO and membranes were developed using
chemiluminescence with either the ECL kit (Amersham Biosci-
ences) or the SuperSignal West Dura kit (Pierce). Quantification of
western blots was performed on a densitometer (Molecular
Dynamics) using the ImagQuant program.
Scanning Electron Microscopy
Experimental and control lines were crossed to flies with the eye
specific GMR-Gal4 driver. Offspring were sorted by genotype and
whole adult flies were sequentially dehydrated in ethanol,
critically-point dried and placed on aluminum mounts. Samples
were coated with a platinum alloy for a thickness of 50 nm and
flash carbon coated. Drosophila heads were then analyzed with a
JEOL JSM-5900 scanning electron microscope.
L3 Wing Vein Assays
Experimental and control lines were crossed to flies with the C5-
Gal4 driver and cultured at 25uC. Once the offspring had eclosed,
flies were sorted by genotype and each individual wing was scored
under a light microscope for extra vein tissue near or attached to
the L3 wing vein. Wings were removed from flies and mounted in
DPX Mounting Medium (Electron Microscopy Sciences).
Climbing Assay
Experimental and control lines were crossed to flies with the CHA-
Gal4 driver and cultured at 25uC. Virgins were collected of each
genotypeandsorted into batchesof20 flies.Flieswere enclosedinside
two clean, unused 9.25 cm culturing tubes that had been taped
together, for a total height of 18.5 cm. Flies were tapped down to the
bottom of the vial and permitted 18 seconds to climb within both
tubes to the top. At the end of 18 seconds, flies were scored as to
whether their final position was either above or below 7 cm. Each
group was trained inthisprocedure for 10 trials and then tested for 10
trials. Trials were performed between 3–6 pm.
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Experimental and control lines were crossed to flies with the
ubiquitous Actin5c-Gal4 driver and cultured at 25uC. Salivary
glands were dissected from third instar larvae, fixed with
formaldehyde, and squashed according to standard protocols.
Samples were blocked with PBT with 0.2% BSA and 5% horse
serum to reduce background. Primary antibodies for MeCP2 were
used (1:100, Affinity and 1:200, Upstate). The secondary
immunofluorescence goat anti-rabbit Cy3 antibody was used at
a 1:200 dilution. The slides were also treated with an RNase
cocktail (1:1000, Ambion) and then TOTO-3 (1:2000, Molecular
Probes) to stain the DNA for confocal microscopy. Slides were
then mounted with a drop of Vectashield containing DAPI in
order to visualize the DNA by eye. Images were collected by
confocal microscopy using the AxioVision and ImageJ programs.
Supporting Information
Figure S1 Overexpression of the novel genetic modifier osa
enhances the MeCP2 external eye phenotype. MeCP2 driven by
GMR-Gal4 at 27.5uC causes increased disorganization of the
ommatidia and interommatidial bristles compared to controls (A–
B). This disorganization is increased when combined with an
overexpression allele of the chromatin remodeling gene osa such
that the overall size of the eye is smaller, ommatidia are
indistinguishable, there are no interommatidial bristles, and
necrotic spots are visible, as shown with arrow (C). Overexpression
of osa alone by GMR-Gal4 also disrupts the external eye structure
(D), but to a much milder degree as compared to co-expression
of MeCP2 and osa. Genotypes: A, GMR-Gal4/+. B, GMR-Gal4:
UAS-MeCP2
FLM119-2M/+. C, GMR-Gal4:UAS-MeCP2
FLM119-2M/
UAS-osa. D, GMR-Gal4/UAS-osa.
Found at: doi:10.1371/journal.pgen.1000179.s001 (3.3 MB TIF)
Figure S2 Genetic modifiers do not alter protein levels of whole
MeCP2 or phosphorylated S423 MeCP2. Western blots were
performed using the heads of flies expressing MeCP2 by GMR-
Gal4 in the presence of modifiers involved in chromatin
remodeling (A) and kinases (B). Key genetic modifiers that were
found to be the most consistently validated in the external eye
assay and secondary assays are marked with an asterisk. All
modifiers were compared to the two MeCP2 positive controls on
the same blot. Quantification by densitometry failed to find a
significant alteration of MeCP2 levels in the case of modifiers as
compared to the variation in the internal positive controls.
Found at: doi:10.1371/journal.pgen.1000179.s002 (1.9 MB TIF)
Figure S3 Genetic modifiers of the full-length MeCP2 eye
phenotype modify MeCP2 D166 in a similar manner. Light
microscopy images of the external eye of Drosophila expressing the
MeCP2 D166 allele and the indicated modifier genes. Control is
shown in A. All flies cultured at 29uC. Genotypes: A, GMR-
Gal4:UAS-MeCP2 D166/+.B ,GMR-Gal4: UAS-MeCP2 D166/
Sin3A
dQ4. C, GMR-Gal4: UAS-MeCP2 D166/crol
e0407. D, Smr
e04389/
+; GMR-Gal4: UAS-MeCP2 D166/+.E ,GMR-Gal4:UAS-MeCP2
D166/UAS-osa.F ,GMR-Gal4:UAS-MeCP2 D166/UAS-pbl. G,
GMR-Gal4:UAS-MeCP2 D166/+; UAS-Scm/+.H ,GMR-Ga-
l4:UAS-MeCP2 D166/+; trx
E2/+. I, GMR-Gal4:UAS-MeCP2
D166/Asx
XF23. J, GMR-Gal4:UAS-MeCP2 D166/+; corto
c03244/+.
K, GMR-Gal4:UAS-MeCP2 D166/+; osa
00090/+. L, GMR-Ga-
l4:UAS-MeCP2 D166/+; UAS-trc
LD/+. M, GMR-Gal4:UAS-MeCP2
D166/+; pbl
09645/+. N, GMR-Gal4:UAS-MeCP2 D166/+;
Scm
e01989/+.
Found at: doi:10.1371/journal.pgen.1000179.s003 (9.8 MB TIF)
Figure S4 Genetic modifiers of the full-length MeCP2 eye
phenotype in the context of the MeCP2 R294X allele. Light
microscopy images of the external eye of Drosophila expressing the
MeCP2 R294X allele and the indicated modifier genes. Control is
shown in A. All flies cultured at 27.5uC. Note that partial loss of
function of Sin3A (panel D) suppresses the MeCP2 R294X
phenotype shown in A, while it enhances the full-length MeCP2
eye phenotype (see Figures 3B and 3C). Likewise, the trx
E2 allele
suppresses the MeCP2 R294X phenotype (compare panels A and
P), while it enhances the full-length MeCP2 eye phenotype (see
Figures 4B and 3I). All other genetic modifiers have similar effects
on full-length MeCP2 and MeCP2 R294X phenotypes, although
the genetic interactions may be evident with some but not all
alleles of each modifier genes (see Table 1). Genotypes: A, GMR-
Gal4:UAS-MeCP2 R294X/+.B ,GMR-Gal4: UAS-MeCP2 R294X/
crol
c04670. C, Smr
e04377/+; GMR-Gal4: UAS-MeCP2 R294X/+.
D,GMR-Gal4: UAS-MeCP2 R294X/Sin3A
dQ4. E, GMR-Gal4:UAS-
MeCP2 R294X/Asx
XF23. F, GMR-Gal4:UAS-MeCP2 R294X/+;
corto
c03244/+. G, GMR-Gal4:UAS-MeCP2 R294X/+; osa
00090/+. H,
GMR-Gal4:UAS-MeCP2 R294X/+; pbl
5/+. I, GMR-Gal4:UAS-
MeCP2 R294X/+; UAS-trc
LD/+. J, GMR-Gal4:UAS-MeCP2
R294X/Asx
1.K ,GMR-Gal4:UAS-MeCP2 R294X/UAS-osa.L ,
GMR-Gal4:UAS-MeCP2 R294X/UAS-pbl. M, GMR-Gal4:UAS-
MeCP2 R294X/+; pbl
09645/+. N, GMR-Gal4:UAS-MeCP2 R294X/
+; Scm
ET50e/+. O, GMR-Gal4:UAS-MeCP2 R294X/+; trx
E2/+. P,
GMR-Gal4:UAS-MeCP2 R294X/+; trx
1/+.
Found at: doi:10.1371/journal.pgen.1000179.s004 (8.5 MB TIF)
Table S1 Drosophila homologs of known MeCP2 Interactors.
Found at: doi:10.1371/journal.pgen.1000179.s005 (0.07 MB
DOC)
Video S1 Neuronal specific overexpression of MeCP2 results in
motor dysfunction. Flies aged 30 days after eclosion are shown in a
climbing assay. After being tapped to the bottom of the vial, flies
are given 18 seconds to climb past 7 cm, marked by a line on the
tube. The control flies (left side, blue) show good climbing ability,
while MeCP2 transgenic flies (right side, red) do not perform well.
Found at: doi:10.1371/journal.pgen.1000179.s006 (3.0 MB
MOV)
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